Clinical Biochemistry andMolecularMedicine inCurrent Oncology
Reykjavik, September 1998
The course program, revised January 23, 1998.
23. September
8.45- 9.00
9.00 -9.45
10.15- 11.00
11.00- 11.45
14.00
24. September
8.30-9.15
9.15- 10.00
10.30- 11.15
11.15 - 12.00
14.00
25. September
8.30-9.15
9.15- 10.00
10.30- 11.15
11.15- 12.00
14.00
26. September
8.30-9.15
9.15-10.00
10.30- 11.15
11.15 - 12.00
28
Welcome - Elfn Ölafsdottir
Epidemiology of cancer - Hrafn Tulinius
Cell cycle control - Sigurour logvarsson
DNAmetabolism, an overview-Jon Johannes Jonsson
Laboratory session in the afternoon
DNA repair and genorne instability - Jorunn E. Eyfjöro
Cancer susceptibility genes - SimonGayther, UK
Molecular genetics of colon cancer- Sigurour logvarsson
MoJecular genetics of breast cancer - SteinunnThorlacius
Informal discussion. Ethics of cancer screening and
councelling families with cancer syndromes
ReynirArngrimsson moderator
Histochemical cancer markers - Diana Barnes, UK
Turnor markers in body fluids - Ulf-Håkan Stenman, FIN
Hereditary malformations and cancer- Jon Johannes Jonsson
Aneuploidy in cancer andmarkers reflecting turnor cell proliferation
Helgi Sigurosson
Application of turnor markers in clinical oncology - a panel discussion
Siguour Björnsson (chair), Diana Barnes, Ulf-Håkan Stenman
Turnor neovascularization - Unnur Petursdottir, USA
Proteases in cancer - fsleifur Ölafsson
Turnor markers in hematological malignancies -Viihelmina Haraldsdottir
Detection ofmutatedcells in body fluids (tentative) - David Sidranski, USA
Klinisk Kemi
i
Norden
J,
1998
